The estimated Net Worth of Ian Michael Estepan is at least $6.02 millió dollars as of 30 August 2024. Mr Estepan owns over 5,985 units of Sarepta Therapeutics Inc stock worth over $4,358,327 and over the last 4 years he sold SRPT stock worth over $976,060. In addition, he makes $684,115 as Exec. VP & CFO at Sarepta Therapeutics Inc.
Mr has made over 3 trades of the Sarepta Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 5,985 units of SRPT stock worth $822,100 on 30 August 2024.
The largest trade he's ever made was exercising 6,250 units of Sarepta Therapeutics Inc stock on 21 June 2024 worth over $802,438. On average, Mr trades about 1,033 units every 14 days since 2020. As of 30 August 2024 he still owns at least 33,946 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Mr Estepan stock trades at the bottom of the page.
Ian Michael Estepan is the Exec. VP & CFO at Sarepta Therapeutics Inc.
As the Exec. VP & CFO of Sarepta Therapeutics Inc, the total compensation of Mr Estepan at Sarepta Therapeutics Inc is $684,115. There are 8 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.
Mr Estepan is 45, he's been the Exec. VP & CFO of Sarepta Therapeutics Inc since . There are 15 older and 2 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry és M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: